Vanguard Group’s ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE) ECTE Stock Holding History

Vanguard Group’s Portfolio ECTE Stock Details ECTE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-251,837	Closed	-$327K	–	4159
2016 Q2	$327K	Buy	251,837 +5,932	+2%	+$9.5K	﹤0.01%	3865
2016 Q1	$332K	Buy	245,905 +100	+0%	+$119	﹤0.01%	3865
2015 Q4	$349K	Buy	245,805 +300	+0.1%	+$482	﹤0.01%	3905
2015 Q3	$381K	Hold	245,505	–	–	﹤0.01%	3922
2015 Q2	$413K	Buy	245,505 +8,800	+4%	+$14.7K	﹤0.01%	3913
2015 Q1	$504K	Buy	236,705 +5,900	+3%	+$13.8K	﹤0.01%	3827
2014 Q4	$312K	Hold	230,805	–	–	﹤0.01%	3829
2014 Q3	$194K	Buy	230,805 +21,800	+10%	+$39.3K	﹤0.01%	3898
2014 Q2	$472K	Buy	209,005 +300	+0.1%	+$745	﹤0.01%	3699
2014 Q1	$626K	Buy	208,705 +73,084	+54%	+$241K	﹤0.01%	3596
2013 Q4	$426K	Hold	135,621	–	–	﹤0.01%	3631
2013 Q3	$374K	Hold	135,621	–	–	﹤0.01%	3601
2013 Q2	$338K	Buy	+135,621	New	+$711K	﹤0.01%	3561

Other funds holding ECTE

Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return

AIM

Acrospire Investment Management Chicago, Illinois $33K AUM 23.36% 1-Year Est. Return

Vanguard Group's ECTE Position: Q3 2016 in Review

Vanguard Group sold out of ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE) (ECTE) in Q3 2016, closing a stake of 251,837 shares — an estimated $327K sold.

Vanguard Group first reported a position in ECTE in Q2 2013 and held it in 13 quarters. The position peaked at $626K in Q1 2014. 2 funds tracked by Wall St. Rank hold ECTE as of Q3 2016.

Vanguard Group reported no remaining ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE) position as of Q3 2016 after selling out during the quarter.
Vanguard Group sold 251,837 ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE) shares in Q3 2016, an estimated $327K.
Vanguard Group first reported a position in ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE) in Q2 2013 and held it in 13 quarters.
Vanguard Group's ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE) position peaked at $626K in Q1 2014.
2 funds tracked by Wall St. Rank held ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE) as of Q3 2016.

Based on Vanguard Group's 13F filing for Q3 2016, filed 14 Nov 2016.